Cited by 1,268Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline

Näslund, Jan·2000·JAMA

DOI 10.1001/jama.283.12.1571

Open this paper in CoChat — free account

Abstract

CONTEXT: Alzheimer disease (AD) is characterized neuropathologically by the presence of amyloid beta-peptide (Abeta)-containing plaques and neurofibrillary tangles composed of abnormal tau protein. Considerable controversy exists as to whether the extent of accumulation of Abeta correlates with dementia and whether Abeta alterations precede or follow changes in tau. OBJECTIVES: To determine whether accumulation of Abeta correlates with the earliest signs of cognitive deterioration and to define the relationship between Abeta accumulation and early tau changes. DESIGN, SETTING, AND PATIENTS: Postmortem cross-sectional study of 79 nursing home residents with Clinical Dementia Rating (CDR) scale scores of 0.0 to 5.0 who died between 1986 and 1997, comparing the levels of Abeta variants in the cortices of the subjects with no (CDR score, 0.0 [n = 16]), questionable (CDR score, 0.5 [n = 11]), mild (CDR score, 1.0 [n = 22]), moderate (CDR score, 2.0 [n = 15]), or severe (CDR score, 4.0 or 5.0 [n = 15]) dementia. MAIN OUTCOME MEASURES: Levels of total Abeta peptides with intact or truncated amino termini and ending in either amino acid 40 (A(beta)x-40) or 42 (A(beta)x-42) in 5 neocortical brain regions as well as levels of tau protein undergoing early conformational changes in frontal cortex, as a function of CDR score. RESULTS: The levels of both A(beta)x-40 and A(beta)x-42 were elevated even in cases classified as having questionable dementia (CDR score = 0.5), and increases of both peptides correlated with progression of dementia. Levels of the more fibril-prone A(beta)x-42 peptide were higher than those of A(beta)x-40 in nondemented cases and remained higher throughout progression of disease in all regions examined. Finally, increases in A(beta)x-40 and A(beta)x-42 precede significant tau pathology at least in the frontal cortex, an area chosen for examination because of the absence of neuritic changes in the absence of disease. CONCLUSIONS: In this study, levels of total A(beta)x-40 and A(beta)x-42 were elevated early in dementia and levels of both peptides were strongly correlated with cognitive decline. Of particular interest, in the frontal cortex, Abeta was elevated before the occurrence of significant tau pathology. These results support an important role for Abeta in mediating initial pathogenic events in AD dementia and suggest that treatment strategies targeting the formation, accumulation, or cytotoxic effects of Abeta should be pursued.

Integrity signals

Registry

Crossref · 10.1001/jama.283.12.1571

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Amyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370
Mechanisms of Neuronal Degeneration in Alzheimer's Disease
Yankner, B. A. (1996) · Neuron · doi:10.1016/s0896-6273(00)80115-4 · Cited by 953
Alzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 879
Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide
Haass, C., & Selkoe, D. J. (1993) · Cell · doi:10.1016/0092-8674(93)90312-e · Cited by 686
Tau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic Deficits
Bierer, L. M., Haroutunian, V. H., Gabriel, S., Knott, P. J., Carlin, L. S., Purohit, D. P., Perl, D. P., Schmeidler, J., Kanof, P. D., & Davis, K. L. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020749.x · Cited by 580

Show all 28 references

Sorted by citations

Items 901–1,000 of 1,000

Secretases as therapeutic targets in Alzheimer’s disease: patents 2000 – 2004
Larner, A. J. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.10.1403 · Cited by 16
Ameliorative Effects of Different Transcranial Electrical Stimulation Paradigms on the Novel Object Recognition Task in a Rat Model of Alzheimer Disease
Zarifkar, A. H., Zarifkar, A., Nami, M., Rafati, A., Aligholi, H., & Vafaee, F. (2019) · Galen Medical Journal · doi:10.31661/gmj.v8i0.1440 · Cited by 15
Optimized Electrode Placements for Non-invasive Electrical Stimulation of the Olfactory Bulb and Olfactory Mucosa
Çakmak, Y. Ö., Nazim, K., Thomas, C., & Datta, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.581503 · Cited by 15
Amyloid Beta-Mediated Changes in Synaptic Function and Spine Number of Neocortical Neurons Depend on NMDA Receptors
Back, M. K., Ruggieri, S., Jacobi, E., & von Engelhardt, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126298 · Cited by 15
A solvatofluorochromic dye as a fluorescent lifetime-based probe of β-amyloid aggregation
Espinar‐Barranco, L., Paredes, J. M., Orte, Á., Crovetto, L., & García‐Fernández, E. (2022) · Dyes and Pigments · doi:10.1016/j.dyepig.2022.110274 · Cited by 15
Novel peptidomimetics as BACE-1 inhibitors: Synthesis, molecular modeling, and biological studies
Butini, S., Gabellieri, E., Brindisi, M., Casagni, A., Guarino, E., Huleatt, P. B., Relitti, N., Pietra, V. L., Marinelli, L., Giustiniano, M., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.011 · Cited by 15
Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivomodel of Alzheimer’s disease
Löffler, T., Flunkert, S., Havas, D., Schweinzer, C., Uger, M. D., Windisch, M., Steyrer, E., & Hutter‐Paier, B. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-84 · Cited by 15
Perturbation of the F19-L34 Contact in Amyloid β (1-40) Fibrils Induces Only Local Structural Changes but Abolishes Cytotoxicity
Hoffmann, F., Adler, J., Chandra, B., Mote, K. R., Bekçioğlu-Neff, G., Sebastiani, D., & Huster, D. (2017) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.7b02317 · Cited by 15
Seeding and Growth of β-Amyloid Aggregates upon Interaction with Neuronal Cell Membranes
Ruiz‐Arias, A., Paredes, J. M., Biase, C. D., Cuerva, J. M., Girón, M. D., Salto, R., Gonzalez‐Vera, J. A., & Orte, Á. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145035 · Cited by 15
Characterization of cognition alteration across the course of the disease in APP751SL mice with parallel estimation of cerebral Aβ deposition
Blanchard, J., Decorte, L., Noguès, X., & Micheau, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.02.005 · Cited by 17
Viral capsid assembly as a model for protein aggregation diseases: Active processes catalyzed by cellular assembly machines comprising novel drug targets
Marreiros, R., Müller‐Schiffmann, A., Bader, V., Selvarajah, S., Dey, D., Lingappa, V. R., & Korth, C. (2014) · Virus Research · doi:10.1016/j.virusres.2014.10.003 · Cited by 15
Early and Late Pathomechanisms in Alzheimer’s Disease: From Zinc to Amyloid-β Neurotoxicity
Szutowicz, A., Bielarczyk, H., Zyśk, M., Dyś, A., Ronowska, A., Gul‐Hinc, S., & Klimaszewska‐Łata, J. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2154-z · Cited by 15
Exploring a Mathematical Model for the Kinetics of β-Amyloid Molecular Imaging Probes through a Critical Analysis of Plaque Pathology
Shoghi, K. I., Barrio, J. R., Kepe, V., & Huang, S. (2006) · Molecular Imaging and Biology · doi:10.1007/s11307-006-0037-4 · Cited by 15
Genetic discoveries as the basis of personalized therapy: rosiglitazone treatment of Alzheimer's disease
Hsueh, W. A. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500383 · Cited by 15
A Super-Resolved View of the Alzheimer’s Disease-Related Amyloidogenic Pathway in Hippocampal Neurons
Yu, Y., Gao, Y., Winblad, B. G., Tjernberg, L. O., & Schedin‐Weiss, S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215008 · Cited by 14
Protective effects of L-carnitine against beta-amyloid-induced memory impairment and anxiety-like behavior in a rat model of Alzheimer's disease
Tork, Y. J., Naseri, E., Basir, H. S., & Komaki‬, A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176879 · Cited by 14
Semantic dementia with lower motor neuron disease showing FTLD-TDP type 3 pathology (sensu Mackenzie)
Östberg, P., & Bogdanović, N. (2010) · Neuropathology · doi:10.1111/j.1440-1789.2010.01154.x · Cited by 15
Does statin use affect amyloid beta deposition and brain metabolism?
Nabizadeh, F., Valizadeh, P., Balabandian, M., & Initiative, A. D. N. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14117 · Cited by 14
Neuropathologic Assessment of Dementia Markers in Identical and Fraternal Twins
Iacono, D., Volkmann, I., Nennesmo, I., Pedersen, N. L., Fratiglioni, L., Johansson, B. E. A., Karlsson, D., Winblad, B. G., & Gatz, M. (2014) · Brain Pathology · doi:10.1111/bpa.12127 · Cited by 14
Amyloid-β-stimulated plasminogen activation by tissue-type plasminogen activator results in processing of neuroendocrine factors
Kranenburg, O., Gent, Y. Y. J., Romijn, E. P., Voest, E. E., Heck, A. J. R., & Gebbink, M. F. B. G. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.11.044 · Cited by 14
Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry
Matthews, C. Z., & Woolf, E. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.12.025 · Cited by 14
Chapter 4. Secretase inhibitors as therapeutics for Alzheimer's disease
Olson, R. E., & Thompson, L. A. (2000) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(00)35005-9 · Cited by 14
Dementia at old age: a clinical end-point of atherosclerotic disease
Blauw, G. J. (2001) · European Heart Journal Supplements · doi:10.1016/s1520-765x(01)90133-6 · Cited by 14
The Role of Aβ-Peptide on Spatial Memory, EEG, Auditory Evoked Potentials And Nicotinic Cholinergic Receptors in A/P Transgenic Mice
Wang, J. (2003) · Cited by 14
Aß Toxicity in Alzheimer’s Disease
Klein, W. L. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-006-3_1 · Cited by 14
Genetics of Psychosis in Alzheimer Disease
DeMichele‐Sweet, M. A. A., & Sweet, R. A. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0030-1 · Cited by 13
Subtle learning and memory impairment in an idiopathic rat model of Alzheimer's disease utilizing cholinergic depletions and β-amyloid
Deibel, S. H., Weishaupt, N., Regis, A. M., Hong, N. S., Keeley, R. J., Balog, R. J., Bye, C. M., Himmler, S. M., Whitehead, S. N., & McDonald, R. J. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.033 · Cited by 13
GFP-based red-emissive fluorescent probes for dual imaging of β-amyloid plaques and mitochondrial viscosity
Leng, H., Yang, J., Long, L., Yan, Y., Shi, W., Zhang, L., & Yan, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106540 · Cited by 13
Neuroprotective Potential of Raloxifene via G-Protein-Coupled Estrogen Receptors in Aβ-Oligomer-Induced Neuronal Injury
Nohara, T., Tsuji, M., Oguchi, T., Momma, Y., Ohashi, H., Nagata, M., Ito, N., Yamamoto, K., Murakami, H., & Kiuchi, Y. (2023) · Biomedicines · doi:10.3390/biomedicines11082135 · Cited by 13
A Unified View of Assessing the Pro‐oxidant versus Antioxidant Nature of Amyloid Beta Conformers
Mitra, S., Prasad, P., & Chakraborty, S. (2018) · ChemBioChem · doi:10.1002/cbic.201800446 · Cited by 13
Soluble Oligomers of the Amyloid β-Protein: Impair Synaptic Plasticity and Behavior
Selkoe, D. J. (2008) · Springer eBooks · doi:10.1007/978-3-540-76330-7_8 · Cited by 13
18F-FDG-PET and Multimodal Biomarker Integration: A Powerful Tool for Alzheimer’s Disease Diagnosis
Bouter, Y., Glasnek, R. M., Wenzel, J., & Bouter, C. (2025) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-025-00932-2 · Cited by 13
Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood–Brain Barrier
Zhou, A. L., Swaminathan, S. K., Salian, V. S., Wang, L., Curran, G. L., Min, H.-K. P., Lowe, V. J., & Kandimalla, K. K. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00784 · Cited by 12
Homotaurine: A failed drug for Alzheimer’s disease and now a nutraceutical for memory protection
Swanoski, M. T. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080576 · Cited by 12
Deletion of Wnt10a Is Implicated in Hippocampal Neurodegeneration in Mice
Zhang, J.-H., Tasaki, T., Tsukamoto, M., Wang, K., Kubo, K., & Azuma, K. (2022) · Biomedicines · doi:10.3390/biomedicines10071500 · Cited by 12
Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues
Torsello, A., Bresciani, E., Ravelli, M., Rizzi, L., Bulgarelli, I., Ricci, G., Ghiazza, B., Puppo, M. D., Mainini, V., Omeljaniuk, R. J., et al. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.06.006 · Cited by 12
La Lunga Attesa : Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease
Villemagne, V. L., Ng, S., Cappai, R., Barnham, K. J., Fodero‐Tavoletti, M. T., Rowe, C. C., & Masters, C. L. (2006) · The Neuroradiology Journal · doi:10.1177/197140090601900406 · Cited by 12
A light at the end of the tunnel – from mutation identification to a potential treatment for Alzheimer’s disease
Lannfelt, L. (2023) · Upsala Journal of Medical Sciences · doi:10.48101/ujms.v128.10316 · Cited by 12
Amyloid-β deposits in human astrocytes contain truncated and highly resistant proteoforms
Beretta, C., Svensson, E., Dakhel, A., Zyśk, M., Hanrieder, J., Sehlin, D., Michno, W., & Erlandsson, A. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103916 · Cited by 12
A review of the application of exercise intervention on improving cognition in patients with Alzheimer’s disease: mechanisms and clinical studies
Wang, M., Yan, H., & Bai, Y. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0046 · Cited by 11
Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment
Lai, S., Zhang, M., Xu, D., Zhang, Y., Qiu, L., Tian, C., & Zheng, J. C. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0028-y · Cited by 11
PET Radioligands for Imaging of Tau Pathology: Current Status
Choe, Y. S., & Lee, K.-H. (2015) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-015-0374-9 · Cited by 11
Decreased Myelinated Fibers in the Hippocampal Dentate Gyrus of the Tg2576 Mouse Model of Alzheimer's Disease
Lü, W., Shu, Y., Zhang, L., Chen, L., Chao, F., Luo, Y., Xiao, Q., Gu, H., Jiang, R., & Tang, Y. C. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314150709 · Cited by 12
Die leichte kognitive Beeinträchtigung
Schröder, J., & Pantel, J. (2007) · Nervenheilkunde · doi:10.1055/s-0038-1626831 · Cited by 11
Matrix metalloproteinase 14 modulates diabetes and Alzheimer’s disease cross-talk: a meta-analysis
Cheng, J., Liu, H.-P., Lee, C.-C., Chen, M.-Y., Lin, W., & Tsai, F. (2017) · Neurological Sciences · doi:10.1007/s10072-017-3166-4 · Cited by 12
Assessment of the Bioactivity of Antibodies against β-Amyloid Peptide in vitro and in vivo
Mohajeri, M. H., Gaugler, M. N. M., Martinez, J., Tracy, J., Li, H., Crameri, A., Kuehnle, K., Wollmer, M. A., & Nitsch, R. M. (2004) · Neurodegenerative Diseases · doi:10.1159/000080981 · Cited by 11
Molecular and cell biological aspects of Alzheimer disease
Shastry, B. S. (2001) · Journal of Human Genetics · doi:10.1007/s100380170011 · Cited by 11
Emerging biology of the cholinergic system across the spectrum of Alzheimer’s disease
Nordberg, A. K. (2006) · International Psychogeriatrics · doi:10.1017/s1041610206003991 · Cited by 11
Implications of Amyloid Precursor Protein and Subsequent β‐Amyloid Production to the Pharmacotherapy of Alzheimer's Disease
Rojas‐Fernandez, C. H., Chen, M., & Fernández, H. L. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.17.1547.34116 · Cited by 11
Erratum: Coexistence of superconductivity and ferromagnetism in the d-band metal ZrZn2
Pfleiderer, C., Uhlarz, M., Hayden, S. M., Vollmer, R., Löhneysen, H. V., Bernhoeft, N., & Lonzarich, G. G. (2001) · Nature · doi:10.1038/35088106 · Cited by 11
Policosanol protects against Alzheimer’s disease-associated spatial cognitive decline in male rats: possible involved mechanisms
Safari, S., Mirazi, N., Ahmadi, N., Asadbegi, M., Nourian, A., Rashno, M., & Komaki‬, A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06317-7 · Cited by 10
Role of PIM Kinase Inhibitor in the Treatment of Alzheimer’s Disease
Meur, S., Mukherjee, S., Roy, S., & Karati, D. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04257-7 · Cited by 10
Ginger leaf polyphenols mitigate β-amyloid toxicity via JNK/FOXO pathway activation in Caenorhabditis elegans
Gao, T., Yan, N., Pu, Y., Zhang, Z., Duan, Z., Tang, Z., Huang, D., Chen, Y., Yuan, S., Yan, X., et al. (2025) · Food & Function · doi:10.1039/d4fo03238a · Cited by 10
Acute Exposure of the Mediobasal Hypothalamus to Amyloid-β 25-35 Perturbs Hepatic Glucose Metabolism
Arrieta‐Cruz, I., Knight, C. M., & Juárez, R. G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-131865 · Cited by 10
Discovery and evaluation of aza-fused tricyclic derivatives for detection of Tau pathology in Alzheimer's disease
Liu, T., Li, Y., Wang, Y., Yan, X., Dai, J., & Cui, M. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114991 · Cited by 10
Lipophilic Analogs of Thioflavin S as Novel Amyloid-Imaging Agents
Wu, C., Cai, L., Wei, J., Pike, V. W., & Wang, Y. (2006) · Current Alzheimer Research · doi:10.2174/156720506777632862 · Cited by 10
Limited Proteolysis Reveals That Amyloids from the 3D Domain-Swapping Cystatin B Have a Non-Native β-Sheet Topology
Davis, P. J., Holmes, D. F., Waltho, J. P., & Staniforth, R. A. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.05.014 · Cited by 10
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Sajadi, A., Provost, C., Pham, B., & Brouillette, J. (2016) · Journal of Visualized Experiments · doi:10.3791/54215 · Cited by 10
Amyloid-β Peptide–Lipid Bilayer Interaction Investigated by Supercritical Angle Fluorescence
Dubois, V., Serrano, D., & Seeger, S. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00264 · Cited by 10
The contingent valuation method in health care. An economic evaluation of Alzheimer's disease.
Nocera, S., Telser, H., & Bonato, D. (2003) · PubMed · Cited by 10
Heparan sulfate proteoglycans: Mediators of cellular and molecular Alzheimer's disease pathogenic factors via tunnelling nanotubes?
Nguyen, D. L., Okolicsanyi, R. K., & Haupt, L. M. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103936 · Cited by 9
REELIN ameliorates Alzheimer's disease, but how?
Katsuyama, Y., & Hattori, M. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.07.004 · Cited by 9
Dissolving microneedle patch integrated with microparticle depots for sustained intradermal delivery of donepezil
Lee, J. H., Song, G. J., Hwang, H. S., & Lee, C. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125653 · Cited by 9
Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
Westwood, M., & Lawson, A. D. G. (2015) · Antibodies · doi:10.3390/antib4030170 · Cited by 9
Role of Membrane Tension Sensitive Endocytosis and Rho GTPases in the Uptake of the Alzheimer’s Disease Peptide Aβ(1-42)
Wesén, E. V., Lundmark, R., & Esbjörner, E. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00053 · Cited by 9
Lead optimization of 4,4-biaryl piperidine amides as γ-secretase inhibitors
Close, J., Heidebrecht, R. W., Hendrix, J., Li, C., Munoz, B., Surdi, L. M., Kattar, S. D., Tempest, P. A., Moses, P., Geng, X., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.038 · Cited by 9
Nanoparticulates
Hubbs, A. F., Porter, D. W., Mercer, R. R., Castranova, V., Sargent, L. M., & Sriram, K. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415759-0.00043-1 · Cited by 9
Influence of Nitric Oxide–Cyclic GMP and Oxidative STRESS on Amyloid-β Peptide Induced Decrease of Na,K-ATPase Activity in Rat Hippocampal Slices
Kawamoto, E. M., Cararo-Lopes, M. M., Kinoshita, P. F., Quintas, L. E. M., Lima, L. S., Andreotti, D. Z., & Scavone, C. (2021) · The Journal of Membrane Biology · doi:10.1007/s00232-021-00196-9 · Cited by 9
Engagement of vascular early response genes typifies mild cognitive impairment
Katsel, P., Fam, P. S., Tan, W., Khan, S., Gama-Sosa, M. A., Gasperi, R. D., Roussos, P., Robinson, A., Cooper, I., Beeri, M. S., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12481 · Cited by 9
Resting state EEG rhythms as network disease markers for drug discovery in Alzheimer's disease
Babiloni, C., Infarinato, F., Triggiani, A. I., Lizio, R., Percio, C. D., Marzano, N., & Richardson, J. C. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2014.02.003 · Cited by 9
Genetic markers in the diagnosis of Alzheimer's disease
Rogaeva, E. A., Tandon, A., & George‐Hyslop, P. S. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3304 · Cited by 10
Molecular Determinants of Alzheimer’s Disease Aβ Peptide Neurotoxicity
Cappai, R., & Barnham, K. J. (2007) · Future Neurology · doi:10.2217/14796708.2.4.397 · Cited by 9
Donepezil in the treatment of patients with Alzheimer’s disease
Waldemar, G. (2001) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.1.1.11 · Cited by 9
Insights into Membrane Damage by α-Helical and β-Sheet Peptides
Rangubpit, W., Distaffen, H. E., Nilsson, B. L., & Dias, C. L. (2025) · Biomolecules · doi:10.3390/biom15070973 · Cited by 8
Nicastrin Overexpression in Transgenic Mice Induces Aberrant Behavior and APP Processing
Goo, J. S., Kim, Y. B., Shim, S. B., Jee, S. W., Lee, S. H., Kim, J. E., Hwang, I. S., Lee, Y. J., Kwak, M. H., Lim, C. J., et al. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8453-3 · Cited by 8
Exploring the Role of Tau Proteins in Alzheimer’s Disease from Typical Functioning MAPs to Aberrant Fibrillary Deposits in the Brain
Shareena, G., & Kumar, D. (2023) · Springer eBooks · doi:10.1007/978-981-99-2657-2_14 · Cited by 8
Systematic In Silico Design, Synthesis, and Biological Studies of Some Novel 1,4-Benzoquinone Derivatives for the Prospective Management of Cognitive Decline
Silakari, P., Silakari, O., & Piplani, P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00092 · Cited by 8
Complex Processes Underlying the Dynamic Changes of D-serine Levels in AD Brains
Ni, X., & Mori, H. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220328123048 · Cited by 8
Oligomeropathies, inflammation and prion protein binding
Forloni, G., Vitola, P. L., & Balducci, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.822420 · Cited by 8
Continuous Flow Reactor for the Production of Stable Amyloid Protein Oligomers
Hayden, E. Y., & Teplow, D. B. (2012) · Biochemistry · doi:10.1021/bi3007687 · Cited by 8
Proteasome Inhibition Augments New Protein Accumulation Early in Long-Term Synaptic Plasticity and Rescues Adverse Aβ Effects on Protein Synthesis
Haynes, K. A., Smith, T. K., Preston, C. J., & Hegde, A. N. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00068 · Cited by 8
The Role of Aβ and Tau Oligomers in the Pathogenesis of Alzheimer’s Disease
Bhaskar, K., & Lamb, B. T. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_5 · Cited by 8
Papain-like Cysteine Proteases and Their Implications in Neurodegenerative Diseases
Brömme, D., & Petanceska, S. S. (2002) · Springer eBooks · doi:10.1007/0-306-46847-6_4 · Cited by 8
BACE1 Inhibition Using 2’-OMePS Steric Blocking Antisense Oligonucleotides
Chakravarthy, M., & Veedu, R. N. (2019) · Genes · doi:10.3390/genes10090705 · Cited by 8
Alzheimer Disease
Selkoe, D. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00067-x · Cited by 9
Brain cholinesterases: I. The clinico-histopathological and biochemical basis of Alzheimer's disease
Shen, Z. X. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.02.032 · Cited by 8
β‐Amyloid immunization approaches for Alzheimer's disease
Imbimbo, B. P. (2002) · Drug Development Research · doi:10.1002/ddr.10070 · Cited by 8
Cellular Limited Proteolysis of Precursor Proteins and Peptides
(2002) · The Enzymes · doi:10.1016/s1874-6047(02)80010-5 · Cited by 8
Modulation of Alzheimer's pathology by cerebro‐ventricular grafting of hybridoma cells expressing antibodies against Aβ in vivo
Gaugler, M. N. M., Tracy, J., Kuhnle, K., Crameri, A., Nitsch, R. M., & Mohajeri, M. H. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.01.002 · Cited by 8
Erratum: correction: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2001) · Nature · doi:10.1038/35088102 · Cited by 8
Silent players, loud impact: unveiling the therapeutic potentials of LncRNAs
Kamal, A., Swellam, M. M., Shalaby, N., Darwish, M. K., & El-Nahrery, E. M. A. (2024) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2023.55 · Cited by 7
Therapeutic Efficacy of the Inositol D-Pinitol as a Multi-Faceted Disease Modifier in the 5×FAD Humanized Mouse Model of Alzheimer’s Amyloidosis
Vera, D. M., López-Gambero, A. J., Verheul-Campos, J., Navarro, J. A., Morelli, L., Galeano, P., Suárez, J., Sanjuan, C., Pacheco-Sánchez, B., Rivera, P., et al. (2024) · Nutrients · doi:10.3390/nu16234186 · Cited by 7
Chemical and Biological Evaluation of the Aqueous Extract of Peumus boldus Molina (Monimiaceae) Leaves
da Silva, B. Y. K., Lopes, A. D. S. N., Maia, P. J. S., Mar, J. M., da Silva, L. S., Sanches, E. A., Corrêa, G. M., Bezerra, J. D. A., & do Carmo, D. F. D. M. (2021) · Pharmacognosy Research · doi:10.5530/pres.14.1.8 · Cited by 7
Role of Neurocellular Endoplasmic Reticulum Stress Response in Alzheimer’s Disease and Related Dementias Risk
Aceves, M., Granados, J., Leandro, A. C., Peralta, J. M., Glahn, D. C., Williams‐Blangero, S., Curran, J. E., Blangero, J., & Kumar, S. (2024) · Genes · doi:10.3390/genes15050569 · Cited by 7
Brain Amyloidosis and BDNF Deficiency Have Opposite Effects on Brain Volumes in AβPP/PS1 Mice Both in vivo and ex vivo
Kärkkäinen, E., Lahtinen, H.-M., Närväinen, J., Gröhn, O. H. J., & Tanila, H. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150059 · Cited by 7
PuF, an antimetastatic and developmental signaling protein, interacts with the Alzheimer’s amyloid-β precursor protein via a tissue-specific proximal regulatory element (PRE)
Lahiri, D. K., Maloney, B., Rogers, J. T., & Ge, Y. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-68 · Cited by 7
Lamotrigine attenuates cerebral ischemia-induced cognitive impairment and decreases β-amyloid and phosphorylated tau in the hippocampus in rats
Han, H., Qian, Q., Yu, Y., Zhao, D., & Sun, G. (2015) · Neuroreport · doi:10.1097/wnr.0000000000000424 · Cited by 7
Effects of Ions and Small Compounds on the Structure of Aβ42 Monomers
Mahmoudinobar, F., Nilsson, B. L., & Dias, C. L. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c09617 · Cited by 7
Immunization with Small Amyloid-β-derived Cyclopeptide Conjugates Diminishes Amyloid-β-Induced Neurodegeneration in Mice
Mulder, C. K., Dong, Y., Brugghe, H. F., Timmermans, H., Tilstra, W., Westdijk, J., van Riet, E., STEEG, H. V., Hoogerhout, P., & Eisel, U. L. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151136 · Cited by 7
Untitled work
Cole (2000) · doi:10.1002/1097-0029(20000815)50:4

Authors: Näslund, J.
Affiliations: Rockefeller University (US)
Corresponding author: Näslund, Jan
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2000-03-22
Volume: 283
Issue: 12
Pages: 1571
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.283.12.1571
OpenAlex: W2000706612
Cited by: 1,268
References: 28
Citations by year: 2026: 9 · 2025: 14 · 2024: 32 · 2023: 23 · 2022: 28 · 2021: 32 · 2020: 31 · 2019: 29 · 2018: 34 · 2017: 29 · 2016: 57 · 2015: 56 · 2014: 60 · 2013: 59 · 2012: 65
FWCI: 40.95
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Aging (AG-02219, AG 05138, P50AG005138, AG 14996, P01AG002219)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: amyloid-beta, Alzheimer's disease, cognitive decline, dementia progression, tau protein, amyloid-beta 42, Aβ40, frontal cortex, Clinical Dementia Rating, postmortem brain, neocortex, nursing home residents, amyloid plaques, neurofibrillary tangles
MeSH terms: Aged, Aged, 80 and over, Brain, Cognition Disorders, Cross-Sectional Studies, Dementia, Enzyme-Linked Immunosorbent Assay, Female, Frontal Lobe, Humans, Immunoenzyme Techniques, Male, Immunoblotting, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks